Clinical experience with OM-85 BV in upper and lower respiratory tract infections.
The preventive effect of OM-85 BV on recurrent ENT and respiratory tract infections has been documented in a series of clinical trials. This article reviews the more significant controlled clinical trials investigating the efficacy and safety of OM-85 BV in airway infections. The literature reviewed covers all age groups. In summary, the administration of OM-85 BV was associated with a decrease in the number of acute exacerbations, with an increase in the number of patients remaining free from infections and with a decrease in antibiotic consumption. These results indicate the efficacy of oral immunostimulation with the bacterial extract OM-85 BV in all age groups and demonstrate its protective effect against recurrent airway infections.
Derenne
J P
JP
Service de Pneumologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Delclaux
B
B
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001419:Bacteria; D001991:Bronchitis / Q000628:therapy; D002457:Cell Extracts; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012141:Respiratory Tract Infections / Q000628:therapy*; D012852:Sinusitis / Q000628:therapy; D000095983:Bacterial Lysates
D000276:Adjuvants, Immunologic; D002457:Cell Extracts; C030259:Broncho-Vaxom; D000095983:Bacterial Lysates